Citi Reaffirms Their Buy Rating on JD (JD)
Morgan Stanley Downgrades JD Health International to Underweight From Equal-weight; Price Target Is HK$20.40
Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy
Nomura Adjusts JD Health International's Price Target to HK$44 From HK$60, Keeps at Buy
Nomura Adjusts JD Health's Price Target to HK$60 From HK$75, Keeps at Buy
Nomura Adjusts JD Health's Price Target to HK$75 From HK$87, Keeps at Buy